SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia

Conclusions. Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin. Solithromycin has potential to provide an intravenous and oral option for monotherapy for community-acquired bacterial pneumonia.
Clinical Trials Registration. NCT01968733.

Source: Clinical Infectious Diseases - September 25, 2016 Category: Infectious Diseases Authors: File, T. M., Rewerska, B., Vucinic-Mihailovic, V., Gonong, J. R. V., Das, A. F., Keedy, K., Taylor, D., Sheets, A., Fernandes, P., Oldach, D., Jamieson, B. D., for the SOLITAIRE-IV Pneumonia Team Tags: ARTICLES AND COMMENTARIES Source Type: research